Fresenius benefits from drug shortages; Perrigo unloads laxative plant;

> The German healthcare company Fresenius says it realized a 20% jump in first-half earnings in part because its injectable generic drugs unit Kabi has jumped on shortages presented by production problems at competitors. Story

> Contract manufacturer AMRI ($AMRI) says its U.S. work grew $2.2 million in the second quarter, although across all segments it saw a 2% decline in revenue to $42.4 million. Story

> Dukal has instituted a nationwide, voluntary recall of certain lots of its benzalkonium chloride swabs and antiseptic wipes manufactured by Jianerkang Medical Dressing because they may be contaminated with Burkholderia cepacia bacteria. Release

> The European Medicines Agency (EMA) says it is cooperating more with pharmaceutical regulators in Japan on plant inspections as well as many other projects. Story

And Finally... OTC drugmaker Perrigo has sold a manufacturing plant in Florida where it makes laxatives and douche products to Medline Industries, maker of Curad bandages. Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.